Edgewise Therapeutics, Inc. (EWTX) Key Metrics
EWTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.04B
- Enterprise value
- $4.00B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 9.9 10-yr median 2.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.35
EWTX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEWTX valuation Price multiples at each fiscal year-end price.
EWTX returns How much profit the business earns on the capital it uses.
EWTX per-share figures Results divided by the shares outstanding at year-end.
EWTX financial health Debt, liquidity and how easily interest is covered.
EWTX efficiency & capital use Working capital cycle and where the cash goes.
EWTX valuation history
EWTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EWTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EWTX price vs earnings per share
EWTX key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $2.55B | $2.47B | $697.1M | $479.1M | $756.4M | — | — |
| Enterprise value | $2.03B | $2.00B | $384.2M | $131.6M | $475.6M | — | — |
| Price / book | 4.9 | 5.4 | 2.2 | 1.4 | 2.8 | — | — |
| Earnings yield | −6.6% | −5.4% | −14.4% | −3.2% | −5.6% | — | — |
| Free cash flow yield | −5.6% | −4.5% | −14.0% | −12.1% | −4.5% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $24.82 | $26.70 | $10.94 | $8.94 | $15.28 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.63 | −$1.45 | −$1.57 | −$0.29 | −$0.85 | −$0.35 | −$0.19 |
| Operating cash flow per share | −$1.40 | −$1.18 | −$1.44 | −$0.98 | −$0.68 | −$0.30 | −$0.19 |
| Free cash flow per share | −$1.40 | −$1.19 | −$1.53 | −$1.09 | −$0.69 | −$0.30 | −$0.19 |
| Cash per share | $5.15 | $5.09 | $5.00 | $6.57 | $5.67 | $2.62 | $0.48 |
| Book value per share | $5.07 | $4.97 | $5.00 | $6.47 | $5.54 | −$0.68 | −$0.34 |
| Tangible book value per share | $5.07 | $4.97 | $5.00 | $6.47 | $5.54 | −$0.68 | −$0.34 |
| Capex per share | $0.00 | $0.01 | $0.09 | $0.10 | $0.01 | $0.00 | $0.00 |
| Debt per share | $0.04 | $0.05 | $0.08 | $0.08 | — | $3.26 | $0.82 |
| Shares outstanding | 102.9M | 92.4M | 63.7M | 53.6M | 49.5M | 49.2M | 49.2M |
| Change in shares outstanding | +11.4% | +45.0% | +18.9% | +8.3% | +0.6% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −34.2% | −34.4% | −30.1% | −5.0% | −35.0% | — | — |
| Return on assets (ROA) | −32.3% | −32.4% | −28.3% | −4.7% | −20.2% | −21.9% | −38.7% |
| Return on tangible assets | −30.4% | −27.5% | −29.5% | −4.2% | −14.8% | −13.0% | −38.7% |
| Financial health | |||||||
| Total debt | $4.0M | $4.7M | $5.4M | $4.4M | — | $160.2M | $40.3M |
| Cash & short-term investments | $530.1M | $470.2M | $318.4M | $351.9M | $280.8M | $129.1M | $23.7M |
| Net debt | −$526.1M | −$465.4M | −$313.0M | −$347.5M | −$280.8M | $31.1M | $16.6M |
| Debt / equity | 0.01 | 0.01 | 0.02 | 0.01 | — | — | — |
| Debt / assets | 0.01 | 0.01 | 0.02 | 0.01 | — | 1.22 | 1.64 |
| Current ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 | 29.86 | 21.24 |
| Quick ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 | 29.86 | 21.24 |
| Interest coverage | — | — | — | -5.5 | -158.9 | -249.2 | — |
| Working capital | $516.0M | $451.6M | $310.2M | $340.4M | $273.3M | $125.3M | $22.9M |
| Invested capital | −$3.9M | −$6.2M | $5.9M | −$823,000 | −$6.4M | −$2.3M | −$244,000 |
| Tangible asset value | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M | −$33.4M | −$16.9M |
| Net current asset value | $513.0M | $447.9M | $305.8M | $336.6M | $272.9M | −$34.9M | −$17.4M |
| Graham net-net per share | $4.86 | $4.79 | $4.66 | $6.19 | $5.46 | −$0.72 | −$0.36 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | $0 | — | — |
| Capex / depreciation | 0.11 | 0.57 | 3.32 | 10.31 | 2.46 | 1.10 | 1.46 |
| Efficiency | |||||||
| Days payables outstanding | 933.0 | 765.4 | 1,067.4 | 3,374.6 | 3,638.6 | 2,216.6 | 1,979.3 |
| Receivables turnover | — | — | — | 0.00 | 0.00 | — | — |
| Payables turnover | 0.39 | 0.48 | 0.34 | 0.11 | 0.10 | 0.16 | 0.18 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $399,500 | $548,000 | — | — |
| Average payables | $5.8M | $4.8M | $5.1M | $5.0M | $2.7M | $1.1M | $667,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from EWTX's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EWTX valuation and financial ratios
Edgewise Therapeutics earned a return on equity of −34.2% in fiscal 2025. It ended the year with $4.0 million of debt and $530.1 million in cash and short-term investments, a net cash position of $526.1 million. The share count rose 109.1% from 49.2M to 102.9M over 6 years.
See the EWTX income statement, the EWTX chart for price history, or the EWTX stock overview for the latest quote and news.
EWTX key metrics FAQ
What is Edgewise Therapeutics's return on equity?
Edgewise Therapeutics's return on equity (ROE) was −34.2% in fiscal 2025: net income of -$167.8 million on average shareholders' equity of $490.7 million.
How much debt does Edgewise Therapeutics have?
Edgewise Therapeutics had total debt of $4.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Edgewise Therapeutics's free cash flow yield?
Edgewise Therapeutics generated -$143.8 million of free cash flow in fiscal 2025, a free cash flow yield of −5.6% on its market value at year-end ($2.6 billion).
What is Edgewise Therapeutics's current ratio?
Edgewise Therapeutics's current ratio was 19.85 at the end of fiscal 2025: current assets were 19.85 times current liabilities.